Capricor Therapeutics (NASDAQ:CAPR) Receives Buy Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Capricor Therapeutics (NASDAQ:CAPR) in a research report released on Thursday, Benzinga reports. HC Wainwright currently has a $40.00 price target on the biotechnology company’s stock.

CAPR has been the topic of several other reports. StockNews.com upgraded Capricor Therapeutics from a sell rating to a hold rating in a research note on Wednesday, January 24th. Cantor Fitzgerald started coverage on Capricor Therapeutics in a research note on Friday, January 5th. They set an overweight rating and a $8.00 target price on the stock.

Capricor Therapeutics Stock Up 2.2 %

CAPR stock opened at $5.15 on Thursday. Capricor Therapeutics has a twelve month low of $2.68 and a twelve month high of $8.22. The business has a 50 day moving average of $5.58 and a 200 day moving average of $4.34.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Thursday, February 29th. The biotechnology company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.21. Capricor Therapeutics had a negative return on equity of 299.67% and a negative net margin of 88.52%. The company had revenue of $12.09 million during the quarter, compared to analyst estimates of $5.80 million. As a group, sell-side analysts expect that Capricor Therapeutics will post -0.83 EPS for the current fiscal year.

Hedge Funds Weigh In On Capricor Therapeutics

A hedge fund recently bought a new stake in Capricor Therapeutics stock. Jump Financial LLC bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 52,800 shares of the biotechnology company’s stock, valued at approximately $258,000. Jump Financial LLC owned approximately 0.17% of Capricor Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 21.68% of the stock is currently owned by institutional investors.

About Capricor Therapeutics

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.